Depression neurobiology

The following session will cover depression neurobiology within the context of this subject, focusing on the historical monoamine hypothesis of depression, highlighting its benefits and limitations, as well as new insights from neuroimaging that emphasize the importance of dysfunctional brain circuits in depressive disorders. We will discuss the critical role of neuroplasticity, exploring how impairments in synaptic adaptation and neurogenesis contribute to symptoms and how modern treatments can restore these functions. The multifactorial nature of depression will be examined, considering genetic, immune and metabolic factors alongside stress and neurocircuitry. Finally, we will look at how these evolving scientific perspectives are shaping next generation treatments, including rapid acting medications and innovative brain stimulation therapies. We are exploring the neurobiological underpinnings of depression, one of the world's most burdensome health conditions. Historically, the monoamine hypothesis has guided our understanding, attributing depression to deficiencies in key neurotransmitters, serotonin, neurodrenalin, and dopamine. This theory arose from drugs like SSRIs and tricyclic antidepressants, improving symptoms. However, its limitations have led research to expand beyond neurotransmitter deficiencies. While neurotransmitter levels are important, recent advances highlight the role of dysfunctional brain circuits in depression. Neuroimaging reveals that depression involves abnormal connectivity and activity in networks,